Cabazitaxel in Relapsed and Metastatic NSCLC

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2012
The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the fact of its significant activity and its acceptable toxicity profile.
Epistemonikos ID: ce4043a729f43c787702862709be564aaccafcaf
First added on: May 11, 2024